Save Product
Product Details
Synonym
Postfusion glycoprotein F0/post-F protein (RSV)
Source
HRSV (A) Post-fusion glycoprotein F0, His Tag (RSF-V52H6) is expressed from human 293 cells (HEK293).
Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 55.2 kDa. The protein migrates as 47-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Within the expressed region, several mutations were introduced to optimize the protein expression and stability.
The protein is designed as a trimer.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in 0.1 M Sodium citrate, 150 mM NaCl, pH5.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
After reconstitution, this product is stable after storage at -70°C for 3 months.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- For long term storage, the product is stable for up to 3 years at -70°C from date of receipt;
- For short term storage, the product is stable for up to 3 months at 2-8°C from date of receipt.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
HRSV (A) Post-fusion glycoprotein F0, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) is more than 95% and the molecular weight of this protein is around 165-185 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) and HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 μg/mL (100 μL/well) can bind Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) with a linear range of 0.1-4 ng/mL (QC tested).
Protocol
Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 μg/mL (100 μL/well) can bind Recombinant Human Anti-RSV Antibody (AM14) with a linear range of 0.004-0.25 μg/mL. HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) is verified not recoginized by Recombinant Human Anti-RSV Antibody (AM14) (Routinely tested).
Protocol
Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 μg/mL (100 μL/well) can bind Recombinant Human Anti-RSV Antibody (D25) with a linear range of 0.1-2 ng/mL. HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) is verified not recoginized by Recombinant Human Anti-RSV Antibody (D25) in low concentration (Routinely tested).
Protocol
Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 μg/mL (100 μL/well) can bind Recombinant Mouse Anti-RSV F Antibody (5C4) with a linear range of 0.004-0.25 μg/mL. HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) is verified not recoginized by Recombinant Mouse Anti-RSV F Antibody (5C4) (Routinely tested).
Protocol
Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) and HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 μg/mL (100 μL/well) can bind Anti-RSV Fusion Protein Antibody (131-2A) with a linear range of 0.1-1 ng/mL (Routinely tested).
Protocol
Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (MALS verified) (Cat. No. RSF-V52H6) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-RSV-F0 broadly Antibody, Mouse IgG1 (3B4) with a linear range of 0.144-9.197 ng/mL (Routinely tested).
Protocol
Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (MALS verified) (Cat. No. RSF-V52H6) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-RSV-F0 broadly Antibody, Mouse IgG1 (4G2) with a linear range of 0.049-1.563 ng/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
